XML 53 R31.htm IDEA: XBRL DOCUMENT v3.25.4
Other Revenue (Tables)
 12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Net product sales by product were as follows (in millions):
Years Ended December 31,
202520242023
COVID(1)
$1,810 $3,084 $6,671 
RSV8 25 — 
Total $1,818 $3,109 $6,671 
_______
(1)Includes sales of Spikevax and mNEXSPIKE.
The following table summarizes product sales provision for the periods presented (in millions):
Years Ended December 31,
202520242023
Gross product sales $3,304 $4,517 $8,203 
Product sales provision:
Wholesaler chargebacks, discounts and fees
(1,037)(1,141)(976)
Returns, rebates and other fees (1)
(449)(267)(556)
Total product sales provision
$(1,486)$(1,408)$(1,532)
Net product sales $1,818 $3,109 $6,671 
_______
(1)Includes an adjustment of approximately $216 million in 2024, reflecting a reduction in prior year provision estimates, primarily related to returns and chargebacks for the previous COVID vaccine season. Adjustments recorded in 2025 related to prior year provision estimates were not material.
The following table summarizes other revenue for the periods presented (in millions):
Years Ended December 31,
202520242023
Grant revenue$22 $37 $94 
Collaboration revenue (Note 5)
13 48 83 
Licensing and royalty revenue11 42 — 
Stand-ready manufacturing revenue
80 $— $— 
Total other revenue$126 $127 $177 
The following table summarizes grant revenue for the periods presented (in millions):
Years Ended December 31,
202520242023
BARDA$9 $34 $88 
Other grant revenue13 3 6 
Total grant revenue$22 $37 $94 
The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):
Years Ended December 31,
Collaboration Revenue by Strategic Collaborator:202520242023
Vertex$13 $23 $82 
Other— 25 1 
Total collaboration revenue$13 $48 $83